Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959882 | 0.90 | HDAC8 (0.54) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2957682 | 0.83 | HDAC8 (0.52) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2950864 | 0.82 | HDAC8 (0.60) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2950684 | 0.82 | HDAC8 (0.57) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2954604 | 0.82 | MCHR1 (0.59) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL12170909 | 0.81 | HDAC8 (0.53) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL5407246 | 0.81 | MCHR1 (0.58) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2948748 | 0.80 | HDAC8 (0.57) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2956165 | 0.80 | HDAC8 (0.60) | ROCK2HDAC8HDAC6MCHR1ALDH1A1 | |
| SCHEMBL2961099 | 0.80 | MCHR1 (0.56) | ROCK2HDAC8HDAC6MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | claimed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | ROCK2 4334/4885HDAC8 3273/4885HDAC6 2201/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | ROCK2 4221/4885HDAC8 3284/4885HDAC6 2371/4885 |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | ROCK2 4643/4885HDAC8 789/4885HDAC6 393/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | ROCK2 4690/4885HDAC8 980/4885HDAC6 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.